Your browser doesn't support javascript.
loading
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge.
Parseghian, C M; Loree, J M; Morris, V K; Liu, X; Clifton, K K; Napolitano, S; Henry, J T; Pereira, A A; Vilar, E; Johnson, B; Kee, B; Raghav, K; Dasari, A; Wu, J; Garg, N; Raymond, V M; Banks, K C; Talasaz, A A; Lanman, R B; Strickler, J H; Hong, D S; Corcoran, R B; Overman, M J; Kopetz, S.
Afiliação
  • Parseghian CM; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: cparseghian@mdanderson.org.
  • Loree JM; BC Cancer, Vancouver, Canada.
  • Morris VK; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Liu X; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Clifton KK; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Napolitano S; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Henry JT; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Pereira AA; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Vilar E; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA; Division of Cancer Prevention and Population Sciences, Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston,
  • Johnson B; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Kee B; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Raghav K; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Dasari A; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Wu J; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Garg N; Division of Diagnostic Imaging, Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Raymond VM; Guardant Health Inc, Redwood City, USA.
  • Banks KC; Guardant Health Inc, Redwood City, USA.
  • Talasaz AA; Guardant Health Inc, Redwood City, USA.
  • Lanman RB; Guardant Health Inc, Redwood City, USA.
  • Strickler JH; Duke University Medical Center, Durham, USA.
  • Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Corcoran RB; Massachusetts General Hospital Cancer Center, Boston, USA; Department of Medicine, Harvard Medical School, Boston, USA.
  • Overman MJ; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Kopetz S; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Ann Oncol ; 30(2): 243-249, 2019 02 01.
Article em En | MEDLINE | ID: mdl-30462160
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Resistencia a Medicamentos Antineoplásicos / Inibidores de Proteínas Quinases / Células Neoplásicas Circulantes Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Ann Oncol Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Resistencia a Medicamentos Antineoplásicos / Inibidores de Proteínas Quinases / Células Neoplásicas Circulantes Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Ann Oncol Ano de publicação: 2019 Tipo de documento: Article